KPC(SH:600422) Yin He Zheng Quan·2026-03-20 09:45Investment Rating - The report maintains a "Recommended" rating for Kunming Pharmaceutical Group (stock code: 600422) [1] Core Views - The company achieved a revenue of 6.575 billion yuan in 2025, a year-on-year decrease of 21.74%. The net profit attributable to shareholders was 350 million yuan, down 46.00% year-on-year. The non-recurring profit and loss amounted to 243 million yuan, an increase of 6% year-on-year [5] - The decline in performance is attributed to the delayed implementation of centralized procurement and a significant drop in the oral medication segment. The injectable segment, however, showed positive growth [5] - The company is focusing on the silver economy and actively engaging in research and development, with a projected net profit growth of 9.87%, 30.43%, and 19.97% for 2026, 2027, and 2028, respectively [5] Financial Performance Summary - Revenue for 2025 was 6.575 billion yuan, with a projected increase to 6.789 billion yuan in 2026, representing a growth rate of 3.25% [6] - The net profit for 2025 was 350 million yuan, expected to rise to 384 million yuan in 2026, reflecting a growth rate of 9.87% [6] - The gross margin for 2025 was 38.52%, with expectations to improve to 40.00% in 2026 [6] Strategic Initiatives - The company launched a new brand strategy focusing on traditional Chinese medicine, introducing 27 new products covering various health categories [5] - Kunming Pharmaceutical is enhancing its product pipeline by reviving classic formulations and integrating commercial channels to optimize its business model [5] - The company is committed to innovation, with R&D expenditures reaching 149 million yuan in 2025, accounting for 2.27% of revenue [5]